Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of WVE-210201 in Duchenne muscular dystrophy after WVE-DMDX51-001
NL-OMON48665Withdrawn
- Sponsor
- Wave Life Sciences
- Start
- Aug 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of Suvodirsen in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Wave Life Sciences. Primary endpoints: Safety and tolerability, Plasma pharmacokinetics and 8 more. Planned start Aug 2018; status: withdrawn.
02
Drugs
Suvodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON48665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48665.